ReviewCancers2026
Neoadjuvant Therapy for Esophageal Cancer.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative study of the tumor-infiltrating lymphocytes before and after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.Journal of cardiothoracic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer remains one of the most aggressive and fatal malignancies worldwide. Historically, therapeutic strategies relied primarily on neoadjuvant chemotherapy or radiotherapy and surgery, but over the past two decades, randomized controlled trials have driven a major transformation in clinical practice.
methodsThis narrative review synthesizes the evolution of evidence-based management from early cytotoxic regimens to modern, histology-specific treatment pathways. We examine landmark trials establishing the roles of neoadjuvant chemoradiation and chemotherapy, along with emerging data on immunotherapy-including checkpoint inhibitors. Persistent challenges include optimizing treatment selection based on molecular profiling, improving response prediction, and managing toxicity in an aging population.
conclusionsWe conclude by highlighting key gaps in current evidence and outlining future directions and ongoing clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.